Heritage Pharma
Last updated Jul 13, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
6
Clinical Programs
0
Confidence Coverage
79%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Psychiatry
- SSRI
- Antipsychotic
Highest priority development: FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)
Regulatory precedent
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Heritage Pharma.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 79%
Active Signals
2
Investigate Priority
0
Opportunity Score
40
Buyer Quality
7 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJul 13, 2026Score 21FDA Approval Update for Risperidone by Heritage Pharma
Psychiatry · Antipsychotic
- MonitorJul 13, 2026Score 19Heritage Pharma's Sertraline Hydrochloride ANDA Submission Receives AP Status
Psychiatry · SSRI
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)Moderate Confidence · 65%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Guidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology ConsiderationsModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Oncology (Cancer)/Hematologic Malignancies Approval NotificationsHigh Confidence · 95%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Withdrawn | Cancer Accelerated ApprovalsHigh Confidence · 95%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Heritage Pharma right now?
- Which regulatory precedents should Heritage Pharma monitor in Psychiatry and SSRI?
- Which pipeline programs should Heritage Pharma prioritize for competitive review?
- What signals require immediate investigation for Heritage Pharma?
- Summarize the strategic implications of recent developments for Heritage Pharma.
- Where is the greatest uncertainty in Heritage Pharma's competitive positioning?